PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Kiang Wu Hospital104 enrolled

Overview

The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

NPC is a common type cancer in Macau and Southern China. The role of PD-L1 in NPC remains controversial. There many reasons behind these inconsistent findings. We used the SP263 antibody with the standard cut off value of 1% and 5%, which is frequently used for lung cancer and other cancer types. We also plan to include over 150 patients, which will be the largest study in NPC. This will help us to gain insights in NPC.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Nasopharyngeal Carcinoma

Interventions

RadiationRADIATION

Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Above 18 years of age * Locally advanced (stage IIIB) or metastatic (stage IV) NPC * Fresh-frozen tissue samples were available were included * After treatment with curative surgery or radiotherapy in Macau * With follow up data were available Exclusion Criteria: • Enrolment in studies that prohibit any participation in this observational study

Locations (1)

Kiang Wu Hospital

Macao, China

Outcomes

Primary Outcomes

Response rate

Efficacy after radiation

Time frame: Followed up with 12 months after last patient in

Secondary Outcomes

Survival rate

Survival in PD-L1 positive and negative group

Time frame: Followed up with 12 months after last patient in

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.